Why Sanofi Has Received a Negative Outlook from Fitch Ratings
Fitch Ratings views Sanofi’s two recent acquisitions in close succession with a total value of 13.7 billion euros as a risk to its balance sheet.
How the Ablynx Acquisition Strengthens Sanofi’s R&D Strategy
Sanofi (SNY) is consistently investing in and focusing on its R&D (research and development) strategy. The company has a number of key technology platforms driving its multitargeting strategy in R&D.
Ablynx Acquisition Strengthens SNY’s Rare Blood Disorder Platform
Ablynx currently has more than 45 proprietary and partnered programs for the development of new treatments in the therapeutic areas of hematology, inflammation, respiratory disease, oncology, and immuno-oncology.
A Look at Ablynx and Sanofi’s Existing Partnership
On January 29, 2018, Sanofi (SNY) announced that it had agreed to acquire Ablynx (ABLX) for 3.9 billion euros.
Highlights of Sanofi’s 3.9 Billion Euro Ablynx Acquisition
On January 29, 2018, Sanofi announced its acquisition of Belgium-based Ablynx for 45 euros per share, amounting to a total of 3.9 billion euros (or $4.8 billion) in cash.
Sanofi’s $11.6 Billion Bioverativ Acquisition: Highlights
On January 22, 2018, Sanofi announced that it had entered into an agreement with Bioverativ to acquire all of its outstanding shares for $105 per share in cash.